Who is sponsoring NCT03737162?

NCT03737162 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT03737162?

Interventions in NCT03737162: Stent implantation of subclavian artery.

What condition does NCT03737162 study?

NCT03737162 studies Subclavian Occlusion.

Is NCT03737162 still recruiting?

NCT03737162 is currently status unknown. Last updated 9 November 2018.

Last reviewed 2018-11-09 · How we verify

NCT03737162: BASELINE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions

Status unknown NA Last updated 9 November 2018

What this trial tests

NA trial testing Stent implantation of subclavian artery in Subclavian Occlusion in 408 participants. Status unknown.

Timeline

2 April 2018

Primary endpoint
3 April 2020

3 July 2020

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	408
Start date	2 April 2018
Primary completion	3 April 2020
Estimated completion	3 July 2020
Sites	6 locations across China

Drugs / interventions tested

Stent implantation of subclavian artery

Conditions studied

Subclavian Occlusion — all drugs for Subclavian Occlusion →

Sponsor

Xuanwu Hospital, Beijing

Who can join

50 and older, any sex, with Subclavian Occlusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bare-metal stent vs Covered stent with subclavian occlusive lesions to verify the efficacy and safety.Study Design are prospective, multiple center, randomized, open, positive controlled, non-inferiority trail.Case total numbers enrollment predict 408 cases，each group 204 cases.Follow up period for 1 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03737162 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 9 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03737162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing